Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)

NCT02072226 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT02072226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02072226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2014
Completion date
March 22, 2017
Enrollment
313 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

stroke